Schrodinger, Inc. (SDGR)
Stock Price:
$48.78 USD
-3.31 (-6.35%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $48.81 +0.03 (0.06%) Oct 30, 7:59 PM
Key Info
| Market Cap |
3.34B |
| Revenue (ttm) |
95.06M |
| Net Income (ttm) |
-35.45M |
| Shares Out |
55.40M |
| EPS (ttm) |
-0.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$48.78 |
| Previous Close |
$52.09 |
| Change ($) |
-3.31 |
| Change (%) |
-6.35% |
| Day's Open |
51.70 |
| Day's Range |
47.59 - 51.74 |
| Day's Volume |
1,470,650 |
| 52-Week Range |
25.50 - 99.50 |
More Stats
| Market Cap |
3.34B |
| Enterprise Value |
3.07B |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
55.40M |
| Float |
52.55M |
| EPS (basic) |
-0.80 |
| EPS (diluted) |
-0.80 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.12M |
| Short Ratio |
2.94 |
| Short % of Float |
9.75% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
35.18 |
| PB Ratio |
13.64 |
| Revenue |
95.06M |
| Operating Income |
-48.03M |
| Net Income |
-35.45M |
| Free Cash Flow |
n/a |
| Net Cash |
270.91M |
| Net Cash / Share |
3.95 |
| Gross Margin |
51.65% |
| Operating Margin |
-50.52% |
| Profit Margin |
-37.30% |
| FCF Margin |
n/a |
| ROA |
-11.63% |
| ROE |
-18.21% |
| ROIC |
-24.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$87.25*
(78.86% upside)
Low
75.0
Current: $48.78
High
92.0
Target: 87.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 85.54 | 66.64 | 55.69 |
| Revenue Growth | 28.37% | 19.65% | - |
| Gross Profit | 49.09 | 42.94 | 39.80 |
| Operating Income | -38.72 | -27.97 | -19.02 |
| Net Income | -24.57 | -28.43 | -17.39 |
| Shares Outstanding | 44.89 | 43.14 | 34.45 |
| Earnings Per Share | -0.55 | -0.66 | -0.50 |
| Operating Cash Flow | -26.06 | -23.71 | -15.31 |
| Capital Expenditures | -1.84 | -5.26 | -3.70 |
| Free Cash Flow | -27.90 | -28.97 | -19.01 |
| Cash & Equivalents | 86.33 | 84.07 | 36.34 |
| Total Debt | 14.47 | - | - |
| Net Cash / Debt | 71.86 | 84.07 | 36.34 |
| Assets | 155 | 121 | 58.02 |
| Liabilities | 57.01 | 30.60 | 21.07 |
| Book Value | -93.36 | -71.56 | -45.36 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Schrodinger, Inc. |
| Country |
United States |
| Employees |
392 |
| CEO |
Ramy Farid |
Stock Information
| Ticker Symbol |
SDGR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Health Information Services |
| Unique Identifier |
NASDAQ: SDGR |
| IPO Date |
February 6, 2020 |
Description
Schrödinger provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.